Navigation Links
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
Date:5/14/2009

Phase 1: Encouraging Results Observed in CLL Patients Treated With Low Doses of TRU-016

Preclinical Efficacy: TRU-016 is Additive or Synergistic in Combination with Established Therapeutics

Preclinical Mechanism Apoptosis in CLL Cells Occurs Via Distinct Mechanism Compared With Other Therapeutics

SEATTLE, May 14 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of three data presentations on its proprietary product candidate, TRU-016, that will be given at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting May 29 through June 2 in Orlando, Fla. The presentations will include positive data from a Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), a preclinical study demonstrating the additive or synergistic effects of TRU-016 in combination with other therapeutic drugs for the treatment of non-Hodgkin's lymphoma (NHL), and a preclinical study evaluating the effect of TRU-016 on direct apoptosis in CLL cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

Abstract 3017 (May 31, 2009): A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular ImmunoPharmaceutical (SMIP(TM)), in Relapsed and Refractory CLL -- Early Promising Clinical Activity

As of the abstract submission, 10 patients enrolled in the Phase 1 trial had received intravenous doses ranging from 0.03 mg/kg to 3.0 mg/kg of TRU-016. Initial data from the study demonstrates the safety and early signs of efficacy of TRU-016 as shown by a reduction in tumor lymphocyte blood counts, reduction in lymph node and spleen size, and/or an improvement in hematopoiesis, or the production of red blood c
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
2. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
7. Trubion Announces Presentations at Upcoming Investor Conferences
8. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer ... recently participated in the American Urology Association’s (AUA) ... Key opinion leaders in urology presented on the ... renal masses while attendees had the opportunity to ... hands-on labs. Attendees at the Los Angeles, CA ...
(Date:11/26/2014)... ADDISON, TX (PRWEB) November 25, 2014 ... age-defying skincare products, earned three prestigious MarCom Awards for ... , Nerium received a Platinum MarCom Award, the organization’s ... Real Event in St. Louis held in April of ... for more than 14,000 attendees. Additionally, Nerium was awarded ...
(Date:11/26/2014)... Global biostimulants market is expected to reach $2,524.02 ... of 12.5%. In order to cater to the ... impacts, farmers are looking to adopt natural compounds ... effectively & efficiently. Biostimulants are consequently seen as ... investments. , Leading companies in the biostimulants market ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4SoundConnect Appoints Director of Channel Development & Sales 2
... 27 The American Stock Exchange(R),(Amex(R)) today lists ... ticker,symbol CUR. Neuralstem, Inc. is a biotechnology ... cell technology in the field of,regenerative medicine. ... Exchange," said,John McGonegal, Senior Vice President of Amex,s ...
... 27 NovaQuest has,made a strategic investment ... specializing in respiratory,disorders. The investment was part ... million) in the Montreal-based company. Last ... partnering group,of Quintiles Transnational, helps TOPIGEN accelerate ...
... 27 DHA omega-3 innovator,Martek Biosciences announced today that ... featured in new Ricos(R) Cheese Sauce.,Sold to schools throughout ... of,DHA per serving in the standard foodservice packaging of ... 3.5 oz. single serve cup which contains 50 mg,of ...
Cached Biology Technology:NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 2life'sDHA(TM) Featured in New Ricos(R) Cheese Sauce 3
(Date:11/4/2014)... death at the right time might actually help boost ... could help in understanding animal populations, pest control and ... in the journal Trends in Ecology and Evolution ... that the kind of positive population effect an overall ... depends on the size and developmental stage of the ...
(Date:11/4/2014)... Think about the way our bodies are assembled during ... that they are supposed to become a nerve or ... the correct place and alignment? Researchers at the University ... In a new study, UM researchers describe the signaling ... neighbors, at the head-trunk region. Their discovery may have ...
(Date:11/4/2014)... , November 4, 2014   ... market growth   Fuel3D , a developer ... a funding round totaling $6.4 million (£4 million). This funding ... secured earlier this year and paves the way for the ... The funding round was led by Chimera Partners ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... knowledge of growth physiology. Incorrect treatment of bone fractures ... by technical deficiencies than by a misjudgment of the ... of treating fractures of the upper limb, Ralf Kraus ... University Medical Center Mannheim, report in the current issue ...
... 2011) The Jackson Laboratory (JAX), Sackler School of Graduate Biomedical ... unveiled a new mammalian genetics track for PhD students. The ... JAX and Tufts. Combining the faculty and resources of the ... and the faculty and resources at JAX, with its emphasis ...
... University of Texas Health Science Center at Houston (UTHealth) ... study approved by the Food and Drug Administration to ... blood stem cells for traumatic brain injury in children. ... Memorial Hermann Hospital, UTHealth,s primary children,s teaching hospital. ...
Cached Biology News:Jackson Laboratory and Tufts University announce new Ph.D. track in mammalian genetics 2UTHealth studies cord blood stem cells for pediatric traumatic brain injury 2
...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Biology Products: